Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Anika Therapeutics ( (ANIK) ) has provided an announcement.
On February 26, 2026, Anika reported fourth-quarter 2025 revenue of $30.6 million, flat year on year, with gross margin expanding to 63% as Commercial Channel sales grew 22% and OEM revenue fell 12% amid anticipated U.S. pricing pressure. For full-year 2025, revenue declined 6% to $112.8 million while gross margin reached 57%, the company generated $11.2 million in operating cash flow and $4.4 million in free cash flow, and Integrity implant revenue more than doubled to $6 million on rising surgeon adoption.
The company highlighted progress on key pipeline programs, including filing the Hyalofast PMA and receiving FDA feedback in January 2026, completing toxicity studies and initiating a bioequivalence study for Cingal ahead of an NDA submission. Anika also began actions to cut general and administrative expenses in early 2026 following strategic divestitures, targeting millions in annual adjusted EBITDA and stock-based compensation savings, reaffirmed 2026 revenue guidance with expected Commercial growth and relatively flat OEM performance, and continued a $15 million share repurchase program slated to conclude in the second quarter of 2026.
On the governance front, Anika entered into a transition agreement on February 26, 2026, with Executive Vice President, General Counsel and Corporate Secretary Mr. Colleran, who will remain in his role through May 1, 2026, with continued salary, benefits and equity vesting during the transition period. Subject to the conditions of the agreement, he will be eligible for separation pay and benefits under a prior executive retention agreement and has provided the company and its affiliates with a general release of claims, signaling a structured leadership transition for investors and employees.
The most recent analyst rating on (ANIK) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Anika Therapeutics stock, see the ANIK Stock Forecast page.
Spark’s Take on ANIK Stock
According to Spark, TipRanks’ AI Analyst, ANIK is a Neutral.
The score is held back primarily by weak financial performance (declining revenue, substantial losses, and deteriorating free cash flow). Technicals add modest support in the near term (improving momentum versus short/mid-term averages), while valuation remains pressured due to losses (negative P/E). Earnings call takeaways are mixed-to-slightly positive on cost control, maintained guidance, and commercial growth, but are tempered by segment revenue declines, margin pressure, and Hyalofast study challenges.
To see Spark’s full report on ANIK stock, click here.
More about Anika Therapeutics
Anika Therapeutics, Inc., based in Bedford, Mass., is a global leader in osteoarthritis pain management and regenerative solutions focused on early-intervention orthopedics. The company markets products through Commercial and OEM channels, including viscosupplementation brands such as Monovisc and Orthovisc, and is expanding its portfolio with the Integrity implant system and pipeline candidates Cingal and Hyalofast for future U.S. launches.
Average Trading Volume: 150,253
Technical Sentiment Signal: Sell
Current Market Cap: $156.5M
Find detailed analytics on ANIK stock on TipRanks’ Stock Analysis page.